ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 2 of 49
Up
УЖМБС 2018, 3(1): 14–18
https://doi.org/10.26693/jmbs03.01.014
Experimental Medicine and Morphology

Dynamics Of Hematological Parameters In Rats Under The Influence Of The Cytotoxic Preparation Oxaliplatinum And Cytoprotector "Lioliv"

Barder E. G.
Abstract

The article evaluates the results of hematological research of experimental rats using oxaliplatin and lichen at different observation time periods. Materials and methods. A total of 40 rats were examined. контрольных групп вводили физиологический раствор, крысам I группы – оксалиплатин, II группы – сначала лиолив, затем оксалиплатин, III группы – сначала оксалиплатин, затем лиолив. Rats of control groups (2 groups with 5 rats in each group) were injected saline, rats of the 1st group got “Oxaliplatin”, the 2nd group rats were first drugged in with “Lioliv” then “Oxaliplatin”, and the 3rd group III was first doped with :Oxaliplatin” then “Lioliv”. The administration of the drugs was carried out five times every 3rd day of the experiment. The duration of the experiment was 21 days. Results and Discussion. In the first group of animals, the number of platelets per 15 days of the experiment was reduced by 3.4 times, in the second group – by 1.9 times, in the third group – by 2 times. The number of leukocytes in animals was decreased in groups I and III by 2.8 and 1.7 times, respectively. However, in the second group of rats, the number of leukocytes remained unchanged compared with the control group. At 21 days of the experiment, the number of platelets was reduced in the groups of animals in the following way: in the first one –by 2.5 times, in the second – by 1.5, in the third – by 1.9 times compared with the control group. The number of leukocytes was reduced in the second and third groups in 2.1 and 1.6 times respectively. In the 1st the hematological parameters remained unchanged compared with animals of the control group. The dynamics of platelet counts in rat blood indicates an increase in their number after 21 days compared to 15 days of the experiment. The low platelet count for 21 days of the experiment was observed in the first group of animals, the highest rate was in the second group of animals, and was increased by 1.12 times as compared with the indicator for 15 days. The dynamics of the increase in the number of leukocytes from 15 to 21 days of the experiment was established in the first group of animals, but this increase was not significant, as the index did not increase to the control group. In the third group of rats, the number of leukocytes in the blood at 15 and 21 days of the experiment was lower than in the control group. The high content of leukocytes among the experimental groups of rats was in the second group – their number did not differ from the control group for both 15 and 21 days of the experiment. Dynamics of platelets in the blood of animals indicates an increase in their number on the 21st day compared with the 15th day of the experiment. A low platelet count on the 21st day of the experiment was observed in the 1st group of animals, the highest level in the 2nd group of rats, and was increased 1.12 times compared to the 15th day. Conclusions. Thus, when using the cytostatic drug “Oxaliplatin” and the hepatoprotector on the liposomal basis “Lioliv” we observed changes in the number of leukocytes and platelets in the peripheral blood of rats in groups I and III. These changes were the reaction of rats’ organisms to the administration of cytostatics accompanied, as a consequence, by leukocytosis and thrombocytopoiesis. In the second group of animals receiving “Lioliv” before cytostatic administration, the number of leukocytes in the peripheral blood did not decrease by 15 and 21 days of the experiment compared with the control group, in contrast to the groups I and III.

Keywords: rats, experiment, hematology, leukocytes, platelets, Oxaliplatin, Lioliv

Full text: PDF (Ukr) 199K

References
  1. Kryachok IA, Sivak LA, Aleksik EM, i dr. Otsenka gematologicheskoy toksichnosti khimioterapii po skheme FACu bolnykh so zlokachestvennymi opukholyami grudnoy zhelezy. Klinicheskaya onkologiya. 2012; 7 (3): 1–5. [Russian]
  2. Khrichkova TYu, Goldberg VE, Zhdanov VV, i dr. Mekhanizmy gematologicheskoy toksichnosti tsisplatina i kselody v usloviyakh kombinirovannoy terapii bolnykh disseminirovannym rakom zheludka. Byulleten SO RAMN. 2005; 4 (118): 64–8. [Russian]
  3. Nerodo GA, Levchenko NE, Guskova EA, Guskova NK. Strukturnye izmeneniya kletok krovi pod vliyaniem tsitostatikov u bolnykh s retsidivami i metastazami raka sheyki matki (in vitro). Sibirskiy onkologicheskiy zhurnal. 2007; 4 (24): 80–3. [Russian]
  4. Shimizu T, Abu Lila AS, Nishio M, Doi Y, Ando H, Ukawa M, Ishima Y, Ishida T. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatinin mouse model. Cancer Sci. 2017 Sep; 108 (9): 1864–9. https://www.ncbi.nlm.nih.gov/pubmed/28643902. https://www.ncbi.nlm.nih.gov/pmc/articles/5581521. https://doi.org/10.1111/cas.13305.
  5. Zhang B, Wang T, Yang S, Xiao Y, Song Y, Zhang N, Garg S. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. J Control Release. 2016 Sep 28; 238: 10–21. https://www.ncbi.nlm.nih.gov/pubmed/27432750, https://doi.org/10.1016/j.jconrel.2016.07.022.
  6. Laboratorni metodi doslidzhen u biolohiyi, tvarinnitstvi ta veterinarniy meditsini: dovidnik. Za red VV Vlizla. Lviv: SPOLOM, 2012. 764 S. [Ukrainian]
  7. Leontyeva FS, Morozenko DV, Korzh IV, ta in. Intehralni pokazniki leykohrami v otsintsi imunnoho statusu khvorikh na osteoartroz velikikh suhlobiv. Problemi bezperervnoi medichnoi osviti ta nauki: naukovo-praktichniy zhurnal. 2012; 4: 79–83. [Ukrainian]
  8. Hlants S. Mediko-biolohicheskaya statistika: Per s anhl. M: Praktika, 1998. 459 s. [Russian]